$1.80▴ 0.00%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-110.00MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
18th pctvs its own history
Cheap
Its valuation sits in the cheaper end of its own recent range.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
enGene Therapeutics Inc. is pre-profit. It is still burning cash while pre-profit. Its valuation sits in the cheaper end of its own recent range.
Key numbers
Valuation
EPS (TTM)$1.31
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$0.00
TTM (trailing 12 months, through fiscal Q2 FY2026)
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.